Medicine
Uroxatral 10 mg extended-release tablet
Uroxatral 10 mg extended-release tablet is a prescription medicine containing Alfuzosin for oral use, marketed by Advanz Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F)…
Key facts
- Active ingredient (INN)
- Alfuzosin
- Brand
- Uroxatral
- Strength
- 10 mg
- Dosage form
- Extended-release tablet
- Route
- Oral
- Packs
- 100 tablets, 30 tablets
- Marketing authorisation holder
- Advanz Pharma
- Manufacturer
- Advanz Pharma
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F), excursions permitted to 15° to 30°C (59° to 86°F). Protect from light and moisture.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G04CA01 Alfuzosin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 June 2013
- Identifiers
- RxCUI 861132, 861134DailyMed set ID 9fc7f119-f36b-44cf-945d-940160f3afe3NDC 59212-200Application NDA021287
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet, extended release in 1 bottle | 59212-200-10 | Advanz Pharma | 3 June 2013 |
| 30 tablet, extended release in 1 bottle | 59212-200-30 | Advanz Pharma | 18 January 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 12 June 2003 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Alfuzosin 10 mg extended-release tablet.
Other strengths and forms of Alfuzosin
Clinical summary
Alfuzosin is an alpha-adrenergic blocker indicated for the treatment of signs and symptoms of benign prostatic hyperplasia, among other approved uses. It is available as extended-release tablets and tablets for oral use. MedsAcross supplies Alfuzosin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about AlfuzosinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Uroxatral prescribing information (Advanz Pharma) · U.S. National Library of Medicine, DailyMed
Need Uroxatral 10 mg extended-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.